Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres
Abstract Aims There is robust trial evidence for improved overall survival (OS) with immunotherapy in advanced solid organ malignancies. The real‐world long‐term survival data and the predictive variables are not yet known. Our aim was to evaluate factors associated with 3‐year and 5‐year OS for pat...
| Үндсэн зохиолчид: | , , , , , , , |
|---|---|
| Формат: | Өгүүллэг |
| Хэл сонгох: | English |
| Хэвлэсэн: |
Wiley
2023-03-01
|
| Цуврал: | Cancer Medicine |
| Нөхцлүүд: | |
| Онлайн хандалт: | https://doi.org/10.1002/cam4.5468 |